In 1871 was created Danske Bank, which is appeared as Corporate Investor. The fund was located in Europe if to be more exact in Denmark. The leading representative office of defined Corporate Investor is situated in the Copenhagen.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The increased amount of exits for fund were in 2014. Comparing to the other companies, this Danske Bank performs on 9 percentage points less the average number of lead investments. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in less than 2 investment rounds annually. The real fund results show that this Corporate Investor is 20 percentage points more often commits exit comparing to other companies.
The standard case for the fund is to invest in rounds with 5-6 partakers. The meaningful sponsors for the fund in investment in the same round are DNB, Westpac, Wells Fargo. In the next rounds fund is usually obtained by Index Ventures, SLS Venture, Novo Holdings.
The overall number of key employees were 25.
Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund. The fund has specific favorite in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Financial Services, Biopharma. Among the most popular portfolio startups of the fund, we may highlight R3, Devenish Nutrition, Gilfresh Produce. For fund there is a match between the location of its establishment and the land of its numerous investments - Denmark.
Related Funds
| Fund Name | Location |
| Acappella Partners | - |
| Allston Venture Fund | Allston, Massachusetts, United States |
| Alto Partners Multi-Family Office | Central Region, Singapore, Singapore |
| Calibrate Ventures | California, Pasadena, United States |
| Daiwa PI Partners | Japan, Tokyo |
| Early Impact Ventures | California, San Francisco, United States |
| Elige Capital | France, Ile-de-France, Paris |
| Filtro Private Equity ( Silicon Valley ) | California, San Francisco, United States |
| GLG Green Lifestyle | Germany, Hamburg |
| Hezhihe Chuangtou | China, Guangdong, Shenzhen |
| Impact Collective | - |
| Jinsanban Touzi | China, Huangpu, Shanghai |
| Pacifica Enterprises | - |
| Paramount Capital | Memphis, Tennessee, United States |
| PCRS Capital Partners | California, Long Beach, United States |
| SABEY | Seattle, United States, Washington |
| Vanguard Ventures | California, San Jose, United States |
| Wuliangye Yibin | China, Sichuan, Yibin |
| Zhejiang State Enterprise Reform and Development Fund | China, Hangzhou, Zhejiang |
| Zhongdian Health Industry Fund | Beijing, Beijing, China |
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Symphogen | $15M | 22 Jan 2002 | Denmark, Capital Region of Denmark, Denmark |
– Anocca AB closed a $47m Series B financing to further advance the company’s industrialised cellular biology platform and progress its pipeline of TCR-T cellular therapies into Phase I/IIa clinical trials.
– The financing was led by advisor Danske Bank, with Swedbank Robur Ny Teknik, Ramsbury Invest and significant family offices including those of Harald Mix and Robert Andreen joining existing investors including Mellby Gård, Nidoco and co-founder Mikael Blomqvist.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Symphogen | $15M | 22 Jan 2002 | Denmark, Capital Region of Denmark, Denmark |
